In order to determine the clinical efficacy of laparoendoscopic single-site surgery (LESS) for uterine fibroids (UFs), the study population comprises 65 patients who underwent hysteromyoma enucleation in our hospital from January 2020 to September 2021. Among them, 30 patients with conventional multiport laparoscopic myomectomy (MLS-M) are taken as the control group (CG), and the rest 35 patients with laparoendoscopic single-site myomectomy (LESS-M) are taken as the research group (RG). Perioperative indicators and incidence of complications are compared between groups. Measurements of inflammatory factors (IFs) (tumor necrosis factor (TNF)-α, interleukin (IL)-6, and C-reactive protein (CRP)) as well as ovarian function indices (follicle stimulating hormone (FSH), luteinizing hormone (LH), and estradiol (E2)) were carried out by using ELISA. Patients' pain sensation, body image satisfaction, incision aesthetic satisfaction, and quality of life (QOL) are assessed using the Visual Analogue Scale (VAS), Body Image Scale (BIS), Cosmetic Score (CS), and SF-36, respectively. LESS-M is beneficial to patients' early recovery after operation, with little influence on ovarian function and high incision aesthetic satisfaction, which reserves clinical popularization.